This Week in GLP-1: A $149 Pill, Wegovy HD, and Canadian Generic Delays

Here's what happened this week in GLP-1 medications — and every story matters if you're waiting for more affordable options in Canada.

FDA Approves Foundayo — The First GLP-1 Weight Loss Pill You Can Take Without Food or Water Restrictions

This is the biggest story of the week. The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1 — the first oral GLP-1 pill for weight loss that can be taken at any time of day, with no fasting, food, or water restrictions. (Oral Wegovy was approved in December 2025, but requires fasting before and after each dose.)

In clinical trials, patients on the highest dose lost approximately 27 lbs (12.4% body weight) over 72 weeks. The approval took just 50 days — the fastest for a new molecular entity since 2002.

US pricing starts at $149/month self-pay ($25/month with commercial insurance). Shipping via LillyDirect began April 6.

Canada angle: Orforglipron is not yet approved by Health Canada. Based on current projections, a Canadian submission could come in 2026, with availability in 2027. We'll track this closely.

In Case You Missed It: Wegovy HD (7.2 mg) Approved by FDA — Launching in the US This Month

Novo Nordisk's higher-dose injectable semaglutide — Wegovy HD at 7.2 mg — received FDA approval on March 19 and is launching in April. This is triple the current standard dose of 2.4 mg.

The results are significant: 20.7% mean weight loss in clinical trials, compared to ~15% with the current dose. About one-third of patients achieved 25% or greater weight loss. The approval came in just 54 days under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program.

Canada angle: No Health Canada submission for Wegovy HD yet. This is Novo Nordisk's competitive response to Eli Lilly — a stronger injectable to counter the convenience of an oral pill.

Generic Semaglutide in Canada: 9 Applications Under Review, but the Timeline Is Slipping

Health Canada now has 9 generic semaglutide applications under active review from companies including Sandoz, Apotex, Teva, Taro, and Aspen Pharmacare. But the timeline is moving later than originally hoped.

Sandoz has been told its submission doesn't yet meet requirements and needs additional data — pushing its expected launch from early 2026 to Q3 2026 at the earliest. Meanwhile, South Africa's Aspen Pharmacare is targeting approval between May and September, and Toronto-based Vimy Pharma filed its made-in-Canada application earlier this year.

Novo Nordisk is also making moves: Health Canada approved Plosbrio and Poviztra in December 2025 — Novo's own renamed copies of Ozempic and Wegovy. These are identical formulations that could be priced to compete with generics, though no pricing has been announced yet.

When generics do arrive, prices could drop to $100–150/month — down from the current $300–400/month for branded semaglutide. Track the full generic timeline.

Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled

Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage:

• 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024)
• 56% cover for diabetes only (down from 66% in 2024)
• 20% of diabetes-only plans are considering adding obesity coverage

Provincial public drug plans still cover semaglutide only for type 2 diabetes — not for weight loss. But with generic pricing expected to drop below $150/month, more employers may find coverage economically viable. Compare current prices across Canada.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about medications.